1.1
Oseltamivir and zanamivir are recommended, within their marketing authorisations, for the treatment of influenza in adults and children if all the following circumstances apply:
-
national surveillance schemes indicate that influenza virus A or B is circulating (the Health Protection Agency in England [and the equivalent bodies in Wales and Northern Ireland] uses information from a range of clinical, virological and epidemiological influenza surveillance schemes to identify periods when there is a substantial likelihood that people presenting with an influenza-like illness are infected with influenza virus)
-
the person is in an 'at-risk' group as defined in 1.2
-
the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms as per licensed indications.